A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Michael Burgess, MD, PhD
Celgene Corporation
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Mayo Clinic Phoenix
Phoenix, Arizona, United States
- Ucla Division of Hematology Oncology
Los Angeles, California, United States
- Yale Cancer Center
New Haven, Connecticut, United States
- University of Chicago
Chicago, Illinois, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Mar 2016
- Primary completion
- 18 Jul 2018
- Completion
- 18 Jul 2018
- Last update posted
- 18 Oct 2018
- Registered enrollment
- 28
- Registry id
- NCT02641002
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.